

---

## Erratum

---

European Heart Journal (1999) 20, 755–763

# Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population

## The Tromsø Study

H. Schirmer and T. Omland

The correct version of Table 3 for the above article is given below.

**Table 3** Number of subjects with left ventricular hypertrophy and left ventricular ejection fraction  $\leq 45\%$  for increasing levels of N-ANP

N-ANP level (pmol.l <sup>-1</sup> )	0–713	714–1291	>1291	Total	CMH test for general association
LVEF >45% and no LVH	184 (95.3)	138 (83.1)	14 (46.7)	336 (86.4)	
LVEF >45% and LVH	9 (4.7)	26 (15.7)	6 (20.0)	41 (10.5)	
LVEF $\leq 45\%$ and no LVH	0	1 (0.6)	1 (3.3)	2 (0.5)	
LVEF $\leq 45\%$ and LVH	0	1 (0.6)	9 (30.0)	10 (2.6)	
Total	193 (100)	166 (100)	30 (100)	389 (100)	$P < 0.001$
% of total	49.6	42.7	7.7		

\*N-ANP=N-terminal pro-atrial natriuretic peptide; CMH=Cochran-Mantel-Haenszel; LVEF=Left ventricular ejection fraction. LVH=Left ventricular hypertrophy. Column percentages in brackets.